Ironwood Pharmaceuticals market cap IRWD
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $571.7M
- Highest close in our data
- $3.2B
- Jul 2018
Ironwood Pharmaceuticals is worth $571.7M at the close on Nov 2, 2026, at $3.46 a share.
That is up 83% over the last year and down 73% over five years.
Its highest close in our data was $3.2B in Jul 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $571.7M | $495.7M | $850.8M | +10% |
| 2025 | $520.6M | $91.6M | $721.7M | −27% |
| 2024 | $712.1M | $548.9M | $2.4B | −60% |
| 2023 | $1.8B | $1.3B | $1.9B | −6% |
| 2022 | $1.9B | $1.5B | $2B | −0% |
| 2021 | $1.9B | $1.5B | $2.3B | +5% |
| 2020 | $1.8B | $1.5B | $2.1B | −14% |
| 2019 | $2.1B | $1.4B | $2.3B | +38% |
| 2018 | $1.5B | $1.4B | $3.2B | −32% |
| 2017 | $2.2B | $2B | $2.9B | +0% |
| 2016 | $2.2B | $1.2B | $2.4B | +35% |
| 2015 | $1.7B | $1.5B | $2.3B | −21% |
| 2014 | $2.1B | $1.2B | $2.2B | +45% |
| 2013 | $1.4B | $1.1B | $2B | +22% |
| 2012 | $1.2B | $1.1B | $1.6B | −2% |
| 2011 | $1.2B | $1.1B | $1.4B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $599.8M |
| PBYIPuma Biotechnology | $525.5M |
| ARVNArvinas | $491.7M |
| COLLCollegium Pharmaceutical | $770.9M |
| CRMDCorMedix | $420.1M |
| ABUSArbutus Biopharma | $791.4M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.3B |
| ANABAnaptysbio | $1.4B |
| PCRXPacira BioSciences | $1.5B |
| Peer median | $781.2M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Ironwood Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.